A prospective evaluation of the effect of finasteride on prostate health index (phi)

Chiu, Peter Ka‐Fung; Chan, Chun-Hong; Liu, Qinyang; Lau, Sui-Yan; Leung, S. F.; Chan, Yun-Sang; Yuen, Steffi Kar-Kei; Yee, Chi‐Hang; Teoh, Jeremy Yuen‐Chun; Tang, Wai-Lun; Poon, Wing-Tat; Ng, Chi‐Fai

doi:10.1007/s11255-023-03530-3

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finasteride, a 5α-reductase inhibitor, serves as a primary medication for treating BPH by inhibiting the conversion of testosterone to dihydrotestosterone, thus suppressing prostatic gland hyperplasia [4].…”

Section: Introductionmentioning

confidence: 99%

The regular use of Finasteride before Transurethral Laser Resection of the Prostate help to reduce bleeding: a retrospective study in a single center

Wang,

Gong,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To investigate the effect of preoperative administration of finasteride on intraoperative bleeding during transurethral laser resection of the prostate. Materials and methods: We retrospectively analyzed 181 patients who underwent transurethral laser resection of the prostate between Jan 2021 and Dec 2023. Patients were divided into two groups based on whether finasteride were used (n = 99) or not (n = 82). The following parameters were collected: age, height, weight and body mass index (BMI), international prostate symptom score (IPSS), quality of life (QoL) score, prostate‐specific antigen (PSA), prostate volume, operation time, hospital stay, catheterization duration, re‐catheterization , preoperative and postoperative hemoglobin concentrations, preoperative and postoperative serum sodium concentrations, postoperative urinary tract infection (UTI) rate, hospitalization costs. We compared the two groups using Student’s t test, Mann–Whitney U test and χ2 test for quantitative and categorical variables, respectively. Linear regression model was used to identify predictive factors of transurethral laser resection of the prostate. Results: Compared with the non-finasteride group, the finasteride group had a lower bleeding level (Δhemoglobin 3.63±8.73 g/L vs. 8.10±11.14 g/L, p=0.026), and a lower hospitalization costs (22796.89±5482.40 Yuan vs. 25113.27±4510.60 Yuan, p=0.008). In multivariate analyses, the regular use of finasteride (r=-0.237, p=0.002) and level of PSA (r=0.233, p=0.006) was the indepentent predictive factor of intraoperative bleeding during transurethral laser resection of the prostate. Conclusion: The regular use of finasteride before transurethral laser resection of the prostate help to reduce intraoperative bleeding level.

show abstract

Section: Introductionmentioning

confidence: 99%

The regular use of Finasteride before Transurethral Laser Resection of the Prostate help to reduce bleeding: a retrospective study in a single center

Wang,

Gong,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

Jirásko,

Viták,

Pecen

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundThe medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha‐blockers, 5‐alpha reductase inhibitors (5‐ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate‐specific antigen (tPSA), free PSA (fPSA), [−2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA.Patients and MethodsSerum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [−2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin‐based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records.ResultsAlpha‐blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha‐blocker and 5‐ARI dual therapy was associated with reduced levels of fPSA, [−2]proPSA, and PHI. Therapy combining alpha‐blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin‐recognized glycan originating in fPSA.ConclusionBPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.

show abstract

Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression

Singh,

Khan,

Bala

et al. 2023

BMC Chemistry

View full text Add to dashboard Cite

Melanoma presents increasing prevalence and poor outcomes. Progression to aggressive stages is characterized by overexpression of the transcription factor E2F1 and activation of downstream prometastatic gene regulatory networks (GRNs). Appropriate therapeutic manipulation of the E2F1-governed GRNs holds the potential to prevent metastasis however, these networks entail complex feedback and feedforward regulatory motifs among various regulatory layers, which make it difficult to identify druggable components. To this end, computational approaches such as mathematical modeling and virtual screening are important tools to unveil the dynamics of these signaling networks and identify critical components that could be further explored as therapeutic targets. Herein, we integrated a well-established E2F1-mediated epithelial-mesenchymal transition (EMT) map with transcriptomics data from E2F1-expressing melanoma cells to reconstruct a core regulatory network underlying aggressive melanoma. Using logic-based in silico perturbation experiments of a core regulatory network, we identified that simultaneous perturbation of Protein kinase B (AKT1) and oncoprotein murine double minute 2 (MDM2) drastically reduces EMT in melanoma. Using the structures of the two protein signatures, virtual screening strategies were performed with the FDA-approved drug library. Furthermore, by combining drug repurposing and computer-aided drug design techniques, followed by molecular dynamics simulation analysis, we identified two potent drugs (Tadalafil and Finasteride) that can efficiently inhibit AKT1 and MDM2 proteins. We propose that these two drugs could be considered for the development of therapeutic strategies for the management of aggressive melanoma. Graphical abstract

show abstract

A prospective evaluation of the effect of finasteride on prostate health index (phi)

Cited by 3 publications

References 15 publications

The regular use of Finasteride before Transurethral Laser Resection of the Prostate help to reduce bleeding: a retrospective study in a single center

The regular use of Finasteride before Transurethral Laser Resection of the Prostate help to reduce bleeding: a retrospective study in a single center

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression

Contact Info

Product

Resources

About